Moelis & Co financials

  1. Home
  2. Financials
  3. MC
MC CIK 0001596967

Source: EDGAR filings · Built 2026-06-03T02:27:09Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 539.97M 415.39M 141.78M 27.04M 920.55M 388.56M
EBITDA 285.74M 183.39M -32.03M 224.07M 503.16M 270.42M
Net Debt -241.44M -189.23M 29.27M -14.03M -328.32M -5.86M
Return on Equity (ROE) 45.67% 34.30% -7.81% 37.95% 86.49% 45.51%
Return on Assets (ROA) 14.91% 10.99% -2.33% 13.86% 27.19% 18.26%
Debt-to-Equity 0.47× 0.51× 0.61× 0.43× 0.39× 0.41×
Effective Tax Rate 20.72% 22.71% 5.60% 22.02% 21.13% 19.13%
Cash Conversion Ratio 2.22× 2.82× -5.76× 0.20× 2.22× 1.96×
Accruals Ratio -0.18× -0.20× -0.16× 0.11× -0.33× -0.18×
CapEx Coverage 15.86× 35.35× 9.49× 5.54× 57.04× 10.56×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Expenses 1.24B 1.02B 895.10M 769.20M 1.04B 677.57M
Operating Income (Loss) 273.86M 172.94M -40.35M 216.10M 495.92M 265.71M
Income Tax Expense (Benefit) 67.85M 44.52M -1.63M 47.64M 113.33M 51.67M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 508.60M 412.47M 186.42M 206.79M 520.21M 202.48M
Assets 1.74B 1.38B 1.18B 1.22B 1.56B 1.20B
Liabilities 1.06B 899.55M 817.30M 757.93M 1.08B 751.97M
Stockholders' Equity Attributable to Parent 568.44M 441.61M 352.14M 444.50M 489.07M 479.95M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 576.30M 427.49M 158.47M 32.99M 936.98M 429.21M
Payments to Acquire Property, Plant, and Equipment 36.33M 12.09M 16.70M 5.96M 16.43M 40.66M
Net Cash Provided by (Used in) Investing Activities -195.97M 17.11M 48.57M -11.18M -17.01M -39.95M
Net Cash Provided by (Used in) Financing Activities -283.90M -215.10M -229.17M -326.90M -602.54M -351.79M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (MC CIK 0001596967), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

RAPP

Rapport Therapeutics, Inc.

ARTNA

ARTESIAN RESOURCES CORPORATION

HAE

HAEMONETICS CORPORATION